

# Effect of Folate Targeted Immunotherapy on the Survival of Mice with Lung Tumor Implants




Fig. 1

100020-6222360

# 24JK-FBP Tumor Imaging





FIG. 2



Con-pe-g.tif



Con-pe-r.tif



Con-pe-l.tif




FITC-pe-g.tif

↑  
FITC images



FITC-pe-r.tif

↑  
PE images



FITC-pe-l.tif

↑  
Transmitted

Folate-FITC  
Treated

Control

Fig. 3

# Tumor Growth Curve\*




FIG. 4

# Effect of Cytokine Combinations on Folate-Targeted Immunotherapy\*




Fig. 5

# Immunotherapy Update\*




FIG. 6

# Synergistic Effect of FEFITC and IL-2 in Folate-Targeted Immunotherapy




Fig. 7

# The Effect of Mouse NK Cell Depletion on Folate Targeted Immunotherapy\*




Fig. 8



# Development of Cellular Immunity against the Parental M109 Tumor Cells




Fig. 9

-○- FEFITC (1500 nmol/kg), IL-2 (250,000 IU/day), and IFN- $\alpha$  (25,000 U/day)

-●-▲-▼-◆- PBS control groups at respective tumor implantation time points

**FEF1TC-Targeted Immunotherapy:  
the IL-2 dosing effect on i.p. M109 Tumor**




Fig. 10

# IFN- $\alpha$ Further Enhances IL-2-augmented Immunotherapeutic Effect of FEFITC in Mice with Pre-existing Anti-FITC Antibody




Fig. 11

# Effect of Depletion of CD8<sup>+</sup> T cells on Folate-Targeted Immunotherapy




Fig. 12

# The Effect of a Third Cytokine, GM-CSF on Folate-Targeted Immunotherapy

## M109 Lung Carcinoma




Fig. 13

**FEF1C-Targeted Immunotherapy:  
the IFN- $\alpha$  dosing effect on i.p. M109 Tumor**




Fig. 14

# Folate-Targeted Immunotherapy: the effect of DNP as a hapten against i.p. M109 Tumor




Fig. 15

# Synergistic Effect of FEFITC and IFN- $\alpha$ against Intraperitoneal M109 Tumor




Fig. 16



**Folate-DNP Further Enhanced the Therapeutic Effect of  
a High Dose Combination of IL-2 and IFN- $\alpha$  in Mice  
with Pre-existing Anti-DNP Antibody**




Fig. 17